Angiogenic activities are increased via upregulation of HIF-1α expression in gefitinib-resistant non-small cell lung carcinoma cells

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been used to treat patients with non-small cell lung cancer (NSCLC) and activating EGFR mutations; however, the emergence of secondary mutations in EGFR or the acquisition of resistance to EGFR-TKIs can develop and is inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Jeong Eun, Bae, Woom-Yee, Choi, Jae-Sun, Lee, Seung Hyeun, Jeong, Joo-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323004/
https://www.ncbi.nlm.nih.gov/pubmed/34345296
http://dx.doi.org/10.3892/ol.2021.12932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323004/
https://www.ncbi.nlm.nih.gov/pubmed/34345296
http://dx.doi.org/10.3892/ol.2021.12932

Ejemplares similares